Stent thrombosis with drug-eluting stents: Is the paradigm shifting?

Journal of the American College of Cardiology

Volumn 62, Issue 21, 2013, Pages 1915-1921

  Palmerini, Tullio ^a   Biondi Zoccai, Giuseppe ^b   Della Riva, Diego ^a   Mariani, Andrea ^a   Genereux, Philippe ^c   Branzi, Angelo ^a   Stone, Gregg W ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

bare metal stent(s); drug eluting stent(s); stent thrombosis

Indexed keywords

3 (TRIMETHOXYSILYL)PROPYL METHACRYLATE; CHROMIUM; COBALT; EVEROLIMUS; FLUOROPOLYMER; LAURYL METHACRYLATE; METHACRYLOYLOXYETHYL PHOSPHORYLCHOLINE; MOLECULAR SCAFFOLD; PACLITAXEL; PHOSPHORYLCHOLINE; PLATINUM; POLY(ETHYLENE CO VINYL ACETATE); POLY(HEXYL METHACRYLATE); POLY(N BUTYL METHACRYLATE); POLY(STYRENE B ISOBUTYLENE B STYRENE); POLYMER; RAPAMYCIN; STAINLESS STEEL; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTICLE; BARE METAL STENT; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; BLOOD VESSEL WALL; CHRONIC INFLAMMATION; CLINICAL PRACTICE; CORONARY ARTERY RECANALIZATION; DEVICE SAFETY; DISEASE PREDISPOSITION; DRUG ELUTING STENT; DRUG RELEASE; HEALING; HUMAN; HYPERSENSITIVITY; IN-STENT RESTENOSIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK REDUCTION; STENT THROMBOSIS;

EID: 84888210594     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.08.725     Document Type: Review

References (43)

1. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
2. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. E.L. Eisenstein, K.J. Anstrom, and D.F. Kong Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2007 159 168
4. G.W. Stone, A. Rizvi, and W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
5. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Clinical outcomes with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis J Am Coll Cardiol 62 2013 496 504
6. A.T. Ong, E.P. McFadden, E. Regar, P.P. de Jaegere, R.T. van Domburg, and P.W. Serruys Late angiographic stent thrombosis (LAST) events with drug-eluting stents J Am Coll Cardiol 45 2005 2088 2092
7. S. Westphal Concerns prompt some hospitals to pare use of drug coated stents Wall Street Journal June 22, 2006
8. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455
9. P. Wenaweser, J. Daemen, and M. Zwahlen Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study J Am Coll Cardiol 52 2008 1134 1140
10. A.V. Finn, G. Nakazawa, and M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510
11. S.G. Ellis, A. Colombo, and E. Grube Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years J Am Coll Cardiol 49 2007 1043 1051
12. A. Kastrati, J. Mehilli, and J. Pache Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 2007 1030 1039
13. K. Kolandaivelu, R. Swaminathan, and W.J. Gibson Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings Circulation 123 2011 1400 1409
14. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
15. J.J. Popma, B. Weiner, M.J. Cowley, C. Simonton, D. McCormick, and T. Feldman FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations J Interv Cardiol 20 2007 425 446
16. I. Bossi, C. Klersy, and A.J. Black In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty J Am Coll Cardiol 35 2000 1569 1576
17. G.W. Stone, S.G. Ellis, and A. Colombo Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation Circulation 115 2007 2842 2847
18. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
19. L. Mauri, W.H. Hsieh, J.M. Massaro, K.K. Ho, R. D'Agostino, and D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
20. L. Raber, P. Juni, and E. Nuesch Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization J Am Coll Cardiol 57 2011 2143 2151
21. L. Raber, M. Magro, and G.G. Stefanini Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study Circulation 125 2012 1110 1121
22. U. Baber, R. Mehran, and S.K. Sharma Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials J Am Coll Cardiol 58 2011 1569 1577
23. A. de Waha, A. Dibra, and R.A. Byrne Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials Circ Cardiovasc Interv 4 2011 371 377
24. T. Palmerini, A.J. Kirtane, and P.W. Serruys Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials Circ Cardiovasc Interv 5 2012 357 364
25. J. Fajadet, W. Wijns, and G.J. Laarman Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial Circulation 114 2006 798 806
26. D.E. Kandzari, L. Mauri, and J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 4 2011 543 550
27. M.B. Leon, E. Nikolsky, and D.E. Cutlip Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial J Am Coll Cardiol Intv 3 2010 1043 1050
28. K. Rasmussen, M. Maeng, and A. Kaltoft Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
29. E. Camenzind, W. Wijns, and L. Mauri Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 2012 1396 1405
30. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
31. C. von Birgelen, M.W. Basalus, and K. Tandjung A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial J Am Coll Cardiol 59 2012 1350 1361
32. M. Sabate, A. Cequier, and A. Iniguez Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction EuroIntervention 7 2011 977 984
33. F. Song, I. Harvey, and R. Lilford Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions J Clin Epidemiol 61 2008 455 463
34. S. Bangalore, S. Kumar, and M. Fusaro Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
35. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
36. S.L. Chin-Quee, S.H. Hsu, and K.L. Nguyen-Ehrenreich Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings Biomaterials 31 2009 648 657
37. G.G. Stefanini, R.A. Byrne, and P.W. Serruys Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials Eur Heart J 33 2012 1214 1222
38. R.S. Wright, J.L. Anderson, and C.D. Adams 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons J Am Coll Cardiol 57 2011 e215 e367
39. E. Kedhi, G.W. Stone, and D.J. Kereiakes Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials EuroIntervention 8 2012 599 606
40. Palmerini T. Difficult decisions with dual antiplatelet therapy: DES, STEMI, unplanned treatment interruption. Paper presented at: EuroPCR; May 14-17, 2012; Paris, France.
41. Kirtane A, Silber S, Neumann F, et al. The relationship between short and long-term antiplatelet therapy use and stent thrombosis following percutaneous coronary intervention with Resolute zotarolimus-eluting stent. Presented at: American College of Cardiology Scientific Sessions; March 9-11, 2013; San Francisco, CA.
42. W.E. Boden, R.A. O'Rourke, and K.K. Teo Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503 1516
43. F.W. Mohr, M.C. Morice, and A.P. Kappetein Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial Lancet 381 2013 629 638